Clinigen announces that Chris Rigg has resigned with immediate effect as a director to seek a CEO role elsewhere.
Clinigen (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that Chris Rigg has resigned with immediate effect as a director to seek a CEO role elsewhere.
Shaun Chilton, CEO of Clinigen, said:
“On behalf of the Board, I would like to thank Chris for his contribution in the first phase of the integration of Quantum Pharma. We wish him well for the future.”
